Trials / Completed
CompletedNCT00131300
A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is to evaluate the safety and efficacy of Synvisc in patients with symptomatic shoulder osteoarthritis (OA). Patients will be given Synvisc, with the possible administration of a second injection where insufficient symptomatic pain relief was experienced during the 3 month follow up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Synvisc (hylan G-F 20) |
Timeline
- Start date
- 2004-04-01
- Completion
- 2006-02-01
- First posted
- 2005-08-18
- Last updated
- 2015-03-18
Locations
6 sites across 2 countries: France, Germany
Source: ClinicalTrials.gov record NCT00131300. Inclusion in this directory is not an endorsement.